Core Insights - Envoy Medical has received FDA approval to expand its pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant to its final stage, marking a significant milestone for the company [1][2] - The company has strengthened its balance sheet by extinguishing $32 million in debt, which positions it for future growth [3][4] - A transformational capital raise was completed in February 2026, involving established institutional healthcare investors, which will support ongoing clinical trials and future product development [4][5] Financial Performance - For the year ended December 31, 2025, net revenue increased to $241,000 from $225,000 in 2024, primarily driven by sales of the Esteem® FI-AMEI implant and related components [5][21] - Cost of goods sold rose to $874,000, up from $742,000 in 2024, largely due to increased scrap and non-recurring expenses [6][21] - Research and development expenses surged by $2,307,000 to $12,486,000, reflecting additional costs associated with the Acclaim pivotal clinical trial [7][21] - Sales and marketing expenses decreased to $1,220,000 from $1,734,000, attributed to reduced legal fees related to reimbursement work for the Esteem product [8][21] - General and administrative expenses increased by $1,105,000 to $7,931,000, mainly due to severance costs and higher consulting expenses [9][21] Balance Sheet Overview - As of December 31, 2025, total assets were approximately $8.56 million, down from $11.54 million in 2024 [19][20] - Current liabilities increased to $11.56 million from $7.54 million, reflecting higher accounts payable and accrued expenses [20] - The company's stockholders' deficit improved to $(12.16 million) from $(18.84 million) in 2024, indicating a stronger financial position [20] Future Outlook - The company aims to revolutionize hearing health with fully implanted solutions, addressing the needs of millions with severe to profound sensorineural hearing loss [4][5][12] - The Acclaim cochlear implant, which received Breakthrough Device Designation from the FDA in 2019, is expected to be a key product in the company's portfolio [10][13]

Core Insights - Envoy Medical has completed enrollment for its pivotal clinical trial of the fully implanted Acclaim® cochlear implant, marking a significant milestone as the first cochlear implant company to achieve this in the U.S. [1][4] Company Overview - Envoy Medical, listed on NASDAQ as COCH, specializes in innovative hearing health technologies, including fully implanted devices for hearing loss [6]. - The company has previously launched the Esteem® active middle ear implant, which has been commercially available since 2010 [6]. Clinical Trial Details - The pivotal trial for the Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation [4][8]. - The trial involved 56 participants, with the final two patients implanted by Dr. Patrick Antonelli at the University of Florida [2][3]. - Following the completion of enrollment, the study will proceed with follow-up visits and data collection, with a PMA application to be submitted to the FDA after 12 months of data collection [3]. Product Features - The Acclaim cochlear implant is designed for adults with severe to profound sensorineural hearing loss and aims to provide a fully implanted solution without the need for an external processor [7][8]. - The device utilizes a sensor that leverages the natural anatomy of the ear to capture sound, representing a significant advancement over traditional cochlear implants [7].

Core Viewpoint - Envoy Medical has announced the issuance of three new patents, enhancing its intellectual property and competitive position in the cochlear implant industry [1][2]. Patent Issuance - The United States Patent and Trademark Office granted U.S. Patent No. 12,544,564, which focuses on improving the input signal-to-noise ratio in cochlear implant systems [3]. - Two patents were granted in Hong Kong: - HK40102155 relates to a combination hearing aid and cochlear implant system that updates the signal processor based on the status of an external auditory aid [4]. - HK40107235 pertains to electrode impedance diagnostics within cochlear implant systems, allowing for the determination of stimulation parameters based on impedance [5]. Company Strategy and Market Position - The CEO of Envoy Medical emphasized the company's belief in the future of fully implanted devices, highlighting the uniqueness of their approach compared to existing designs [2]. - The strength of the intellectual property portfolio is seen as a strategic asset as the company moves towards potential Premarket Approval (PMA) submission and commercialization [2]. Product Development - The Acclaim® cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently undergoing a pivotal clinical trial in the U.S. [6]. - The Acclaim CI is designed for individuals with severe to profound sensorineural hearing loss and aims to leverage the natural anatomy of the ear for sound capture [9][8]. Company Overview - Envoy Medical is focused on innovative technologies for hearing loss, having developed fully implanted devices like the Esteem® active middle ear implant and the investigational Acclaim® cochlear implant [7].

Core Insights - Envoy Medical experienced a transformational third quarter in 2025, significantly improving its financial position by eliminating $32 million in debt and strengthening its balance sheet [2][5][6] - The company received FDA approval to expand its pivotal clinical trial to the final stage, which is expected to enhance its market position in fully implanted hearing solutions [2][8] - Envoy Medical's net revenue for the third quarter was $42 thousand, a decrease from $56 thousand in the same period of 2024 [5][17] Financial Highlights - Research and Development (R&D) expenses decreased by $57 thousand to $2.7 million compared to the same quarter in 2024, as the company transitioned from development to clinical trial phases [5][17] - General and administrative expenses increased by $752 thousand, primarily due to public company costs and expenses related to a September 2025 offering [5][17] - As of September 30, 2025, the company had approximately $3.556 million in cash, down from $5.483 million at the end of 2024 [6][15] Operational Developments - The company continued to receive additional global patents in the U.S., Europe, and Australia, reinforcing its position as a market leader in fully implanted hearing solutions [2][7] - The Acclaim Cochlear Implant, an investigational device, is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA [8][9] Market Position - Envoy Medical aims to capitalize on its first-mover advantage in the fully implanted hearing solutions market, with ongoing interest in its cochlear implant trial [2][8] - The company is dedicated to advancing hearing technology to improve access and quality of life for individuals with hearing loss [7][8]

Core Insights - Envoy Medical has made significant progress in the third quarter of 2025, focusing on redefining hearing health with fully implanted devices as the standard of care [2][3] Financial Developments - The company eliminated over $32 million in debt, simplifying its capital structure and enhancing shareholder equity [4][3] - This debt elimination allows for a greater focus on strategic growth initiatives to drive shareholder value [5] Patent and Intellectual Property Expansion - Envoy Medical has expanded its global patent portfolio, now holding approximately 38 granted US patents and 40 foreign patents, with seven new patents secured recently [6][3] - The company has solidified its ownership of the "Invisible Hearing" trademark in Australia, complementing existing registrations in the US, UK, and Europe [8][6] Clinical Trial Progress - The pivotal clinical trial for the Acclaim® cochlear implant is progressing as planned, with all 10 patients in the first stage reaching their three-month follow-up visits without serious adverse events [13][3] - The company aims to submit its Premarket Approval (PMA) application to the FDA in 2027 [13] Reimbursement Strategy - New Category III CPT codes for totally-implantable active middle ear implants, including the Esteem® device, took effect on July 1, 2025, enhancing reimbursement potential [16][3] - Positive changes in reimbursement for the Esteem® device could drive broader adoption and create substantial business opportunities for Envoy Medical [17][16] Public Health Impact - Untreated hearing loss is linked to increased dementia risk, emphasizing the importance of timely intervention and the role of Envoy Medical's solutions in supporting long-term brain health [18][19] - The company's fully implanted solutions aim to provide reliable hearing without external devices, addressing both hearing restoration and public health concerns [19] Future Outlook - Envoy Medical is entering the final quarter of 2025 with a strengthened balance sheet, an expanded intellectual property portfolio, and clinical trial momentum, indicating a bright future [20][3] - The company remains committed to redefining hearing health and delivering long-term value to shareholders [21]